[go: up one dir, main page]

HK1257730A1 - 抗despr單克隆抗體用於癌症和中風的靶向療法及成像 - Google Patents

抗despr單克隆抗體用於癌症和中風的靶向療法及成像

Info

Publication number
HK1257730A1
HK1257730A1 HK19100103.3A HK19100103A HK1257730A1 HK 1257730 A1 HK1257730 A1 HK 1257730A1 HK 19100103 A HK19100103 A HK 19100103A HK 1257730 A1 HK1257730 A1 HK 1257730A1
Authority
HK
Hong Kong
Prior art keywords
cancer
stroke
imaging
monoclonal antibody
targeted therapy
Prior art date
Application number
HK19100103.3A
Other languages
English (en)
Inventor
Nelson Ruiz-Opazo
Victoria L M Herrera
Original Assignee
Univ Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Boston filed Critical Univ Boston
Publication of HK1257730A1 publication Critical patent/HK1257730A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK19100103.3A 2015-08-24 2019-01-03 抗despr單克隆抗體用於癌症和中風的靶向療法及成像 HK1257730A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562208937P 2015-08-24 2015-08-24
PCT/US2016/048427 WO2017035249A1 (en) 2015-08-24 2016-08-24 ANTI-DEspR MONOCLONAL ANTIBODY TARGETED THERAPY AND IMAGING FOR CANCER AND STROKE

Publications (1)

Publication Number Publication Date
HK1257730A1 true HK1257730A1 (zh) 2019-10-25

Family

ID=58101030

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100103.3A HK1257730A1 (zh) 2015-08-24 2019-01-03 抗despr單克隆抗體用於癌症和中風的靶向療法及成像

Country Status (6)

Country Link
US (2) US10202457B2 (zh)
EP (1) EP3341413A4 (zh)
AU (2) AU2016311265B2 (zh)
CA (1) CA2995716A1 (zh)
HK (1) HK1257730A1 (zh)
WO (1) WO2017035249A1 (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3696195B1 (en) 2010-07-23 2024-02-14 Trustees of Boston University Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US10202457B2 (en) 2015-08-24 2019-02-12 Trustees Of Boston University Anti-DEspR monoclonal antibody targeted therapy and imaging for cancer and stroke
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JP2020513248A (ja) 2016-10-19 2020-05-14 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響による親和性細胞抽出
CN111356475A (zh) * 2017-09-18 2020-06-30 波士顿大学董事会 用于治疗NETosis和中性粒细胞激活的方法
WO2019118921A1 (en) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Acoustic transducer drive and controller
US10953107B2 (en) 2018-06-15 2021-03-23 Trustees Of Boston University Polypeptide compositions and methods for site-specific targeting of therapeutic agents
EP4041771A4 (en) * 2019-10-09 2023-11-08 The Council of the Queensland Institute of Medical Research TARGETING EPHA3 AND ITS USES
US11584792B2 (en) 2020-10-15 2023-02-21 Trustees Of Boston University Antibody therapies and methods for treating coronavirus infection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5969098A (en) 1997-06-06 1999-10-19 Cyberchemics, Inc. Yeast-toxin-related protein for antimicrobial vaccine and sterilizing preservative use
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
US20040242851A1 (en) * 2001-06-26 2004-12-02 Zhenping Zhu Bispecific antibodies that bind to vegf receptors
WO2006055665A2 (en) 2004-11-16 2006-05-26 Trustees Of Boston University Roles for dual endothelin-1/angiotensin ii receptor (dear) in hypertension and angiogenesis
DK1988167T3 (da) 2005-02-17 2020-07-13 Univ Sorbonne Intracellulære inhiberende peptider
WO2007089911A2 (en) 2006-01-30 2007-08-09 The Scripps Research Institute Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
JP2009060790A (ja) 2006-03-01 2009-03-26 Suntory Ltd 酵母に乾燥耐性および／または低温保存耐性を付与する活性を有するタンパク質をコードする遺伝子及びその用途
JP2011529080A (ja) 2008-07-24 2011-12-01 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド 癌幹細胞を標的とする治療法
ES2636087T3 (es) 2009-03-31 2017-10-05 Ligand Pharmaceuticals Inc. Un antagonista de receptores de endotelina y angiotensina II de bifenilsulfonamida para tratar la glomeruloesclerosis
EP3696195B1 (en) 2010-07-23 2024-02-14 Trustees of Boston University Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
WO2015051152A1 (en) 2013-10-03 2015-04-09 Leuvas Therapeutics Modulation of leukocyte activity in treatment of neuroinflammatory degenerative disease
WO2016127255A1 (en) 2015-02-10 2016-08-18 Palaniyar Nadesalingam Mediation of inflammatory response using inhibitors of netosis
US10202457B2 (en) 2015-08-24 2019-02-12 Trustees Of Boston University Anti-DEspR monoclonal antibody targeted therapy and imaging for cancer and stroke

Also Published As

Publication number Publication date
US11236169B2 (en) 2022-02-01
US20170058036A1 (en) 2017-03-02
EP3341413A1 (en) 2018-07-04
EP3341413A4 (en) 2019-07-17
AU2016311265A1 (en) 2018-03-08
WO2017035249A1 (en) 2017-03-02
AU2023202436A1 (en) 2023-06-29
US10202457B2 (en) 2019-02-12
CA2995716A1 (en) 2017-03-02
AU2016311265A9 (en) 2023-03-16
US20190153106A1 (en) 2019-05-23
AU2016311265B2 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
HK1257730A1 (zh) 抗despr單克隆抗體用於癌症和中風的靶向療法及成像
HK1245134A1 (zh) 用抗lap單克隆抗體治療癌症
IL275547A (en) Antigen-binding proteins target co-antigens
ZA202001285B (en) Antigen-binding proteins targeting shared antigens
HK1252272A1 (zh) 使用抗ox40抗體治療癌症的方法
DK3458478T3 (da) Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
PL3331910T3 (pl) Przeciwciała monoklonalne przeciwko ludzkiemu antygenowi dojrzewania limfocytów B (BCMA)
IL277861A (en) Antibodies specific to AXL for cancer treatment
ZA202000851B (en) Antibodies useful in cancer diagnosis
SG11201707949XA (en) Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy
IL268460A (en) Treatment of bladder cancer with an antibody against pd-l1
HK1243434A1 (zh) Igf-1r抗體及其診斷癌症的用途
SG11201703292VA (en) ANTI HUMAN Gas6 MONOCLONAL ANTIBODY
HK1248730A1 (zh) Igf-1r抗體及其用於癌症診斷的用途
IL280421A (en) Cancer treatment by antibody
DK3344287T3 (da) Anti-survivin-antistoffer til cancerterapi
GB201813138D0 (en) Cancer treatment with an antibody
GB201509493D0 (en) Therapeutic antibody